News

PipelineReview.com22h

Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006 to Clinical Proof-of-Concept

SCHLIEREN/ZURICH, Switzerland I August 12, 2025 I Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived ...
PipelineReview.com22h

Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology

Collaboration focuses on developing a KRAS G12D inhibitor, complementing Bayer’s precision oncology development portfolio in the areas of pancreatic, ...
PipelineReview.com22h

First FDA-Approved Treatment for MacTel Performed

CUMBERLAND, RI, USA I August 11, 2025 I Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic ...
PipelineReview.com22h

Fosun Pharma’s Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million

SHANGHAI, China I August 11, 2025 I On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a ...
PipelineReview.com22h

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

NEW YORK, NY, USA I August 11, 2025 I Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
PipelineReview.com23h

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

FORT LEE, NJ, USA I August 11, 2025 I Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of ...
PipelineReview.com23h

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

BASEL, Switzerland I August 12, 2025 I Novartis today announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus ...